Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions”In the company’s words, NCT04513366 on ClinicalTrials.gov
- Tested for
- Chronic Gout (2 trials)
- Main trialPhase 3
- “This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). Analysis of primary and key efficacy was performed at Day 28 of Treatment Period 6. Safety was…”In the company’s words, NCT04513366 on ClinicalTrials.gov
Other drugs for Chronic Gout
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- EtoricoxibLaboratorios Silanes S.A. de C.V. · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SSGJ-6133SBio · Phase 2
- PRX-115Protalix · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 21 Jul 2022 | A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy | |
| Phase 3Completed | 10 Jan 2023 | A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026